INTRODUCTION {#sec1-1}
============

Radical nephroureterectomy (RNU) with bladder cuff excision is the current standard of care for upper tract urothelial carcinoma (UTUC). However, postoperative survival outcomes are still unsatisfactory, and a large portion of patients inevitably experience disease recurrence and possible death after surgery. Therefore, it is essential to identify patients who might experience the greatest benefit from RNU and neoadjuvant therapy.[@ref1][@ref2]

Thus far, some preoperative and postoperative factors have been used in the risk stratification of UTUC, based on the European Association of Urology (EAU) guidelines.[@ref3] Although tumor stage and grade have been commonly adopted by most urologists to assess the prognosis of patients with cancer, many researchers have begun to explore the potential roles of certain blood-based biomarkers in the risk stratification of UTUC.

Increasing evidence suggests that specific homeostatic factors might play a pivotal role in tumor invasion and metastasis.[@ref4][@ref5][@ref6] Plasma fibrinogen, one of the major components in the coagulation pathway, is often synthesized in large quantities by cancer cells.[@ref7] A growing body of literature has indicated the association of elevated fibrinogen levels with worse survival outcomes in prostate,[@ref8] ovarian,[@ref9] lung,[@ref10] bladder,[@ref11] and renal cell cancers.[@ref12] Similarly, several studies have investigated the predictive value of fibrinogen in patients with UTUC.[@ref13][@ref14][@ref15] Nevertheless, most of these were small sample studies with varying cutoff values for fibrinogen, likely limiting, to some extent, its clinical value for prognostic evaluation.

Therefore, the present study aimed to further validate whether fibrinogen can provide an independent parameter for the assessment of pathological and survival outcomes after RNU in a large cohort with UTUC. In addition, because neutrophil-to-lymphocyte ratio (NLR) is the only serum biomarker recommended in UTUC based on EAU guidelines,[@ref3] we also sought to assess the clinical utility of fibrinogen versus NLR in multivariate models.

PATIENTS AND METHODS {#sec1-2}
====================

 {#sec2-1}

### Study population {#sec3-1}

This study was approved by the Committee for Ethics of West China Hospital, Chengdu, China. Between January 2003 and December 2016, 820 consecutive patients were pathologically diagnosed as having UTUC after RNU at the Department of Urology & Institute of Urology, West China Hospital, Chengdu, China. In this study, patients\' data were collected from their clinical medical records, and the formal consent is not required due to its respective nature. We excluded patients with coagulation-related diseases or prior anticoagulant therapy (*n* = 7); inflammatory or autoimmune diseases (*n* = 17); nonurothelial carcinomas (*n* = 13); lack of preoperative fibrinogen data (*n* = 16); and those who were lost to first follow-up (*n* = 64). Finally, a total of 703 patients with available fibrinogen data within 2 weeks before surgery were qualified and included in our study for further analysis.

All patients had received RNU, which was performed according to the standard procedures (dissection of the kidney with the whole length of the ureter and open bladder cuff excision). Open or laparoscopic RNU was performed in accordance with the urologists\' judgment. Lymph node dissection was performed only in patients with suspected enlarged lymph nodes, which were confirmed via preoperative radiology assessment (computed tomography or magnetic resonance imaging) or intraoperative discovery. When lymph node dissection was performed, the following templates were used: for tumors located in the right pelvis and the upper and middle ureter, dissection included the right renal hilar, paracaval, retrocaval, and inter-aortocaval nodes; for tumors located in the left pelvis and the upper and middle ureter, dissection included the left renal hilar and para-aortic nodes; and for tumors located in the lower ureter, dissection included the ipsilateral common iliac, external iliac, obturator, internal iliac, and presacral nodes.

### Clinicopathological evaluation {#sec3-2}

All RNU specimens were independently re-evaluated by two experienced pathologists. Tumor grade and stage were determined based on the World Health Organization/International Society of Urologic Pathology classification of 2004 and the 2002 Union for International Cancer Control tumor node metastasis (TNM) classification system, respectively.[@ref4] Information on tumor architecture (sessile or papillary), lymphovascular invasion (LVI), positive surgical margins (PSM), and concomitant variant histology (CVH, urothelial carcinomas with abnormal histological differentiation) was retrieved from related pathological reports. Preoperative laboratory data, including fibrinogen level, platelet count, white blood cell (WBC) count, alkaline phosphatase (ALP) level, lactate dehydrogenase (LDH) level, NLR, and albumin-to-globulin ratio (AGR), were collected within 2 weeks before surgery (if more than one report was available, the most recent one was recorded). NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count; AGR was defined as the value of albumin divided by the value of globulin. The optimal cutoff value for fibrinogen was defined as 4.025 g l^−1^, based on the receiver-operating characteristic (ROC) curves. The cutoff values for WBC,[@ref16] platelet count,[@ref16] ALP,[@ref17] LDH,[@ref18] NLR,[@ref19] and AGR[@ref17] were determined as previously reported. In addition, other information, including age, sex, body mass index (BMI), smoking status, tumor side and location, bladder cancer status, hydronephrosis, and multifocality, was documented from the medical record of each patient.

### Follow-up {#sec3-3}

Patients were followed up every 3 months in the first year after RNU, every 6 months for the next 2 years, and annually thereafter. Physical examinations, blood laboratory tests, and chest radiography assessments were routinely performed. Computed tomography or magnetic resonance imaging analyses were performed every year or upon suspected recurrence of the disease.

Disease recurrence was defined as recurrence from the operating site, regional or distant lymph nodes, and/or visceral metastasis. Cancer-specific survival (CSS) was defined as the time from RNU to cancer-related death. Disease recurrence-free survival (RFS) was defined as the time from RNU to disease recurrence. Overall survival (OS) was defined as the time from RNU to death from all causes.

### Statistical analyses {#sec3-4}

Student\'s *t*-test and the Chi-squared test were used to evaluate continuous variables and dichotomous variables. Associations between fibrinogen and adverse pathological outcomes were assessed using logistic regression analysis, in which odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. Probabilities of CSS, RFS, and OS were determined using Kaplan--Meier curves. The log-rank test was used to assess the differences between groups. Multivariate Cox proportional hazard models with forward stepwise methods were used to assess the risk factors for CSS, RFS, and OS. C-index was calculated to assess the improvement in discrimination when adding preoperative laboratory factors to the base model, using the R package "survival." Decision curve analyses were performed to show the benefit of multivariate models that contained preoperative biomarkers. A two-sided probability (*P*) value of \<0.05 was considered statistically significant. Statistical analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS) Statistics version 22.0 (IBM Corp., Armonk, NY, USA).

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Baseline characteristics {#sec3-5}

Of the 703 patients who exhibited UTUC, the median age at RNU surgery was 67 (interquartile range: 59--74) years and the mean fibrinogen level was 3.8 (standard deviation \[s.d.\]: 1.3) g l^−1^. Low- and high-grade UTUC were observed in 186 (26.5%) and 517 (73.5%) patients, respectively. Positive lymph nodes were found in 67 (9.5%) patients. Two hundred and eighty-seven (40.8%) patients had received postoperative adjuvant chemotherapy, and none of the patients had received neoadjuvant therapy. Patients were dichotomized into a high fibrinogen group (fibrinogen ≥4.025 g l^−1^) and a low fibrinogen group (fibrinogen \<4.025 g l^−1^) by ROC curves (**Supplementary Figure 1**). The area under the ROC curve was 0.689, and the Youden index was 0.316, with a sensitivity of 57.8% and a specificity of 74.7%. There were no significant differences between groups regarding age, BMI, smoking status, tumor side and location, bladder cancer status, hydronephrosis, and adjuvant therapy (each *P* \> 0.05). However, differences were observed in terms of gender, multifocality, surgical approach, tumor grade and stage, lymph node status, tumor size, PSM, tumor architecture, CVH, and laboratory biomarkers (*i.e*., WBC, platelet count, ALP, LDH, NLR, and AGR) (all *P* \< 0.05; **[Table 1](#T1){ref-type="table"}**).

###### 

Patients' characteristics in the present study

  Variables                                   Total (n=703)   Fibrinogen \<4.025 g l^−1^ (n=454, 64.6%)   Fibrinogen ≥4.025 g l^−1^ (n=249, 35.4%)   P
  ------------------------------------------- --------------- ------------------------------------------- ------------------------------------------ ---------
  Age (year), mean±s.d.                       65.8±11.4       66.1±11.3                                   65.4±11.4                                  0.680
  Gender, *n* (%)                                                                                                                                    
   Male                                       399 (56.8)      276 (60.8)                                  123 (49.4)                                 0.004
   Female                                     304 (43.2)      178 (39.2)                                  126 (50.6)                                 
  BMI (kg m^−2^), mean±s.d.                   22.6±4.6        22.6±4.7                                    22.5±4.4                                   0.470
  Smoking status, *n* (%)                                                                                                                            
   No                                         502 (71.4)      313 (68.9)                                  189 (75.9)                                 0.051
   Former/current                             201 (28.6)      141 (31.1)                                  60 (24.1)                                  
  Tumor side, *n* (%)                                                                                                                                0.216
   Left                                       359 (51.1)      224 (49.3)                                  135 (54.2)                                 
   Right                                      344 (48.9)      230 (50.7)                                  114 (45.8)                                 
  Bladder cancer status, *n* (%)                                                                                                                     0.688
   No                                         602 (85.6)      386 (85.0)                                  216 (86.7)                                 
   Previous                                   22 (3.1)        16 (3.5)                                    6 (2.4)                                    
   Concomitant                                79 (11.2)       52 (11.5)                                   27 (10.8)                                  
  Hydronephrosis, *n* (%)                                                                                                                            0.166
   No                                         264 (37.6)      179 (39.4)                                  85 (34.1)                                  
   Yes                                        439 (62.4)      275 (60.6)                                  164 (65.9)                                 
  Tumor location, *n* (%)                                                                                                                            0.115
   Pelvicalyceal                              376 (53.5)      233 (51.3)                                  143 (57.4)                                 
   Ureteric                                   203 (28.9)      143 (31.5)                                  60 (24.1)                                  
   Both                                       124 (17.6)      78 (17.2)                                   46 (18.5)                                  
  Multifocality, *n* (%)                                                                                                                             0.032
   No                                         587 (83.5)      369 (81.3)                                  218 (87.6)                                 
   Yes                                        116 (16.5)      85 (18.7)                                   31 (12.4)                                  
  Surgical approach, *n* (%)                                                                                                                         \<0.001
   Open RNU                                   473 (67.3)      284 (62.6)                                  189 (75.9)                                 
   Laparoscopic RNU                           230 (32.7)      170 (37.4)                                  60 (24.1)                                  
  Tumor grade, *n* (%)                                                                                                                               \<0.001
   Low                                        186 (26.5)      156 (34.4)                                  30 (12.0)                                  
   High                                       517 (73.5)      298 (65.6)                                  219 (88.0)                                 
  pT stage, *n* (%)                                                                                                                                  \<0.001
   pTis, pTa, pT1                             217 (30.9)      171 (37.7)                                  46 (18.5)                                  
   pT2                                        145 (20.6)      109 (24.0)                                  36 (14.5)                                  
   pT3                                        241 (34.3)      141 (31.1)                                  100 (40.2)                                 
   pT4                                        100 (14.2)      33 (7.3)                                    67 (26.9)                                  
  Lymph node status, *n* (%)                                                                                                                         \<0.001
   pN0                                        89 (12.7)       56 (12.3)                                   33 (13.3)                                  
   pNx                                        547 (77.8)      373 (82.2)                                  174 (69.9)                                 
   pN+                                        67 (9.5)        25 (5.5)                                    42 (16.9)                                  
  LVI, *n* (%)                                                                                                                                       \<0.001
   No                                         596 (84.8)      403 (88.8)                                  193 (77.5)                                 
   Yes                                        107 (15.2)      51 (11.2)                                   56 (22.5)                                  
  Tumor size (cm), *n* (%)                                                                                                                           \<0.001
   ≤3                                         225 (32.0)      166 (36.6)                                  59 (23.7)                                  
   \>3                                        478 (68.0)      288 (63.4)                                  190 (76.3)                                 
  PSM, *n* (%)                                                                                                                                       0.001
   No                                         646 (91.9)      429 (94.5)                                  217 (87.1)                                 
   Yes                                        57 (8.1)        25 (5.5)                                    32 (12.9)                                  
  Tumor architecture, *n* (%)                                                                                                                        \<0.001
   Papillary                                  221 (31.4)      179 (39.4)                                  42 (16.9)                                  
   Sessile                                    482 (68.6)      275 (60.6)                                  207 (83.1)                                 
  CVH                                                                                                                                                \<0.001
   No                                         543 (77.2)      375 (82.6)                                  168 (67.5)                                 
   Yes                                        160 (22.8)      79 (17.4)                                   81 (32.5)                                  
  Adjuvant chemotherapy, *n* (%)                                                                                                                     0.455
   No                                         416 (59.2)      264 (58.1)                                  152 (61.0)                                 
   Yes                                        287 (40.8)      190 (41.9)                                  97 (39.0)                                  
  Laboratory tests                                                                                                                                   
   Fibrinogen (g l^−1^), mean±s.d.            3.8±1.3         3.1±0.6                                     5.1±1.1                                    \<0.001
   Platelet count (×10^9^ l^−1^), mean±s.d.   198.4±85.7      177.3±64.0                                  237.0±104.8                                \<0.001
   WBC count (×10^9^ l^−1^), mean±s.d.        6.9±2.6         6.4±2.2                                     7.8±3.0                                    \<0.001
   ALP (U l^−1^), mean±s.d.                   81.5±35.9       75.6±22.5                                   92.6±50.8                                  \<0.001
   LDH (U l^−1^), mean±s.d.                   189.1±69.7      179.4±39.4                                  207.4±102.9                                \<0.001
   NLR, mean±s.d.                             3.4±2.0         3.0±1.9                                     4.2±2.0                                    \<0.001
   AGR, mean±s.d.                             1.4±0.3         1.5±0.3                                     1.3±0.3                                    \<0.001
  End points                                                                                                                                         
   Disease recurrence, *n* (%)                291 (41.4)      149 (32.8)                                  142 (57.0)                                 \<0.001
   Cancerrelated death, *n* (%)               204 (29.0)      86 (18.9)                                   118 (47.4)                                 \<0.001
   Overall death, *n* (%)                     253 (36.0)      118 (26.0)                                  135 (54.2)                                 \<0.001

RNU: radical nephroureterectomy; LVI: lymphovascular invasion; CVH: concomitant variant histology; PSM: positive surgical margins; pT: pathological tumor; WBC: white blood cell; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; NLR: neutrophil-to-lymphocyte ratio; AGR: albumin-to-globulin ratio; HR: hazard ratio; s.d.: standard deviation; BMI: body mass index

### Fibrinogen and adverse pathological outcomes {#sec3-6}

We investigated the associations between fibrinogen and adverse pathological features. After adjusting for pretreatment factors, including age, BMI, smoking status, gender, hydronephrosis, tumor side, tumor location, history of bladder cancer, multifocality, platelet count, WBC count, ALP, LDH, NLR, and AGR, multivariate logistic analysis revealed that elevated fibrinogen (treated as a continuous variable) was independently associated with increased risks of high-grade carcinoma (OR: 1.71, *P* \< 0.001), high pathological tumor stage (OR: 1.69, *P* \< 0.001), lymph node involvement (OR: 1.47, *P* = 0.001), LVI (OR: 1.30, *P* = 0.007), sessile carcinoma (OR: 1.45, *P* \< 0.001), CVH (OR: 1.35, *P* = 0.001), and PSM (OR: 1.38, *P* = 0.021) (**[Table 2](#T2){ref-type="table"}**).

###### 

Binary and multivariate logistic regression analysis for fibrinogen level (continuous variable) for pathological outcomes when adjusting for preoperative confounders

  Adverse pathological outcomes   Adjusted OR^a^   95% CI       P
  ------------------------------- ---------------- ------------ ---------
  High-grade disease              1.71             1.36--2.13   \<0.001
  High pT stage (≥ pT3)           1.69             1.40--2.04   \<0.001
  Lymph node involvement          1.47             1.18--1.84   0.001
  LVI                             1.30             1.08--1.57   0.007
  Sessile carcinoma               1.45             1.19--1.78   \<0.001
  CVH                             1.35             1.13--1.61   0.001
  PSM                             1.38             1.05--1.80   0.021

^a^Adjusting for age (continuous), gender, BMI (continuous), smoking status, hydronephrosis, tumor side, tumor location, history of bladder cancer, multifocality, fibrinogen (continuous), platelet count (continuous), WBC count (continuous), ALP (continuous), LDH (continuous), NLR (continuous), and AGR (continuous). LVI: lymphovascular invasion; CVH: concomitant variant histology; PSM: positive surgical margins; pT: pathological tumor; OR: odds ratio; CI: confidence interval; BMI: body mass index; WBC: white blood cell; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; NLR: neutrophil-to-lymphocyte ratio; AGR: albumin-to-globulin ratio

### Fibrinogen and survival outcomes {#sec3-7}

With a median follow-up of 42 (range: 1--168) months, 204 (29.0%) patients died of UTUC, 291 (41.4%) experienced disease recurrence, and 253 (36.0%) died of all causes at the time of the last follow-up. The 5-year CSS, RFS, and OS were 72.9%, 59.3%, and 66.7%, respectively, in the low fibrinogen group, compared with 35.5%, 28.1%, and 30.8%, respectively, in the high fibrinogen group.

Kaplan--Meier curves showed that patients with high fibrinogen levels had lower CSS, RFS, and OS than patients with low fibrinogen levels (log-rank tests, all *P* \< 0.001; **[Figure 1](#F1){ref-type="fig"}**). **[Table 3](#T3){ref-type="table"}** and **[Supplementary Table 1](#T4){ref-type="table"}** show the results from univariate and multivariate Cox regression analyses. Fibrinogen levels \>4.025 g l^−1^ were significantly associated with worse CSS (hazard ratio \[HR\]: 3.97; 95% CI: 3.00--5.24), RFS (HR: 2.86; 95% CI: 2.27--3.60), and OS (HR: 3.28, 95% CI: 2.56--4.21) in the univariate Cox regression model. Multivariate analysis showed that pathological tumor stage, lymph node involvement, tumor size, NLR, and fibrinogen were independent predictors of CSS, RFS, and OS; tumor grade and CVH were independent predictors of CSS and OS; and ALP was an independent predictor of CSS. The HR values of fibrinogen were 2.33, 2.09, and 2.09 for CSS, RFS, and OS, respectively (**[Table 3](#T3){ref-type="table"}**).

![Kaplan--Meier curves and log-rank tests for survival in UTUC patients according to preoperative fibrinogen level (cutoff value: 4.025 g l^−1^). (**a**) Cancer-specific survival, (**b**) disease recurrence-free survival, and (**c**) overall survival. UTUC: upper tract urothelial carcinoma; CSS: cancer-specific survival; RFS: disease recurrence-free survival; OS: overall survival.](AJA-22-177-g001){#F1}

###### 

Forward stepwise multivariate Cox regression analyses of clinicopathological factors predicting survival outcomes in patients with upper tract urothelial carcinoma

  Variables                                          Cancer-specific survival   Recurrence-free survival   OS                                                 
  -------------------------------------------------- -------------------------- -------------------------- ------------------- ---------- ------------------- ---------
  Tumor grade (high *vs* low)                        1.92 (1.17--3.15)          0.010                      --                  --         1.72 (1.15--2.57)   0.009
  pT stage                                                                      \<0.001                                        \<0.001                        \<0.001
  pTis, pTa, pT1                                     Reference                                             Reference                      Reference           
  pT2                                                1.49 (0.85--2.61)          0.164                      1.47 (0.97--2.23)   0.067      1.48 (0.92--2.38)   0.108
  pT3                                                2.48 (1.51--4.08)          \<0.001                    2.36 (1.65--3.38)   \<0.001    2.33 (1.52--3.55)   \<0.001
  pT4                                                3.64 (2.04--6.49)          \<0.001                    3.81 (2.45--5.92)   \<0.001    3.58 (2.17--5.89)   \<0.001
  Lymph node status                                                             \<0.001                                        \<0.001                        0.001
  pN0                                                Reference                                             Reference                      Reference           
  pNx                                                2.13 (1.25--3.62)          0.005                      1.87 (1.23--2.83)   0.003      1.91 (1.22--3.01)   0.005
  pN+                                                3.16 (1.70--5.86)          \<0.001                    3.27 (1.95--5.47)   \< 0.001   2.68 (1.54--4.66)   \<0.001
  Tumor size (\>3 cm *vs* ≤3 cm)                     1.47 (1.02--2.10)          0.037                      1.49 (1.12--1.98)   0.007      1.53 (1.11--2.11)   0.009
  CVH (yes *vs* no)                                  1.45 (1.06--1.98)          0.021                      --                  --         1.36 (1.02--1.80)   0.037
  ALP (≥90 U l^−1^ *vs* \<90 U l^−1^)                1.40 (1.03--1.90)          0.031                      --                  --         --                  --
  NLR (≥2.5 *vs* \<2.5)                              1.83 (1.33--2.52)          \<0.001                    1.56 (1.21--2.01)   0.001      1.67 (1.26--2.20)   \<0.001
  Fibrinogen (≥4.025 g l^−1^ *vs* \<4.025 g l^−1^)   2.33 (1.69--3.20)          \<0.001                    2.09 (1.62--2.70)   \< 0.001   2.09 (1.58--2.77)   \<0.001

CVH: concomitant variant histology; pT: pathological tumor; ALP: alkaline phosphatase; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; CI: confidence interval; --: not included in the analysis; OS: overall survival

###### 

Univariable Cox regression models predicting survival outcomes in patients with upper tract urothelial carcinoma

  Variables                                         Cancer-specific survival   Recurrence-free survival   OS                                                       
  ------------------------------------------------- -------------------------- -------------------------- ---------------------- --------- ----------------------- ---------
  Age (≥65 *vs* \<65 years)                         0.848 (0.641--1.122)       0.249                      0.881 (0.696--1.115)   0.293     0.966 (0.748--1.246)    0.788
  BMI (\>25 *vs* ≤25, kg/m^2^)                      0.848 (0.616--1.169)       0.315                      0.947 (0.729--1.230)   0.681     0.917 (0.691--1.218)    0.551
  Smoking status (former/current *vs* no)           0.844 (0.615--1.159)       0.294                      0.864 (0.664--1.124)   0.275     0.878 (0.662--1.164)    0.364
  Gender (male *vs* female)                         0.824 (0.628--1.081)       0.163                      0.857 (0.682--1.076)   0.184     0.876 (0.686--1.019)    0.290
  Tumor side (right *vs* left)                      1.089 (0.830--1.428)       0.538                      1.063 (0.847--1.333)   0.601     1.051 (0.824--1.341)    0.687
  Bladder cancer status                                                        0.203                                             0.376                             0.136
  No                                                Reference                                             Reference                        Reference               
  Previous                                          0.345 (0.085--1.391)       0.134                      0.903 (0.425--1.920)   0.792     0.297 (0.074--1.198)    0.088
  Concomitant                                       1.205 (0.809--1.795)       0.360                      1.263 (0.901--1.770)   0.176     1.198 (0.835--1.719)    0.327
  Hydronephrosis (yes *vs* no)                      1.249 (0.938--1.664)       0.128                      1.401 (1.097--1.788)   0.007     1.342 (1.035--1.740)    0.026
  Tumor location                                                               0.556                                             0.508                             0.675
  Pelvicalyceal                                     Reference                                             Reference                        Reference               
  Ureteric                                          1.005 (0.729--1.384)       0.978                      0.937 (0.715--1.229)   0.639     0.941 (0.704--1.260)    0.685
  Both                                              1.217 (0.841--1.762)       0.298                      1.152 (0.842--1.577)   0.377     1.118 (0.796--1.569)    0.521
  Multifocality (yes *vs* no)                       1.059 (0.736--1.524)       0.758                      0.993 (0.727--1.358)   0.967     0.971 (0.692--1.361)    0.864
  Surgical approach (Laparoscopic *vs* Open)        0.672 (0.485--0.932)       0.017                      0.858 (0.662--1.114)   0.251     0.711 (0.529--0.956)    0.024
  Tumor grade (high *vs* low)                       3.558 (2.305--5.492)       \<0.001                    2.278 (1.675--3.098)   \<0.001   2.847 (1.992--4.070)    \<0.001
  pT stage                                                                     \<0.001                                           \<0.001                           \<0.001
  pTis, pTa, pT1                                    Reference                                             Reference                        Reference               
  pT2                                               1.632 (0.966--2.757)       0.067                      1.502 (1.011--2.233)   0.044     1.635 (1.045--2.558)    0.031
  pT3                                               3.654 (2.372--5.629)       \<0.001                    2.797 (2.005--3.901)   \<0.001   3.232 (2.222--4.702)    \<0.001
  pT4                                               9.339 (5.921--14.729)      \<0.001                    6.936 (4.811--9.998)   \<0.001   7.955 (5.327--11.881)   \<0.001
  Lymph node status                                                            \<0.001                                           \<0.001                           \<0.001
  pN0                                               Reference                                             Reference                        Reference               
  pNx                                               1.496 (0.915--2.446)       0.109                      1.505 (1.013--2.235)   0.043     1.507 (0.983--2.311)    0.060
  pN+                                               6.124 (3.525--10.638)      \<0.001                    5.546 (3.484--8.831)   \<0.001   5.361 (3.260--8.814)    \<0.001
  LVI (yes *vs* no)                                 2.726 (1.991--3.732)       \<0.001                    2.211 (1.676--2.917)   \<0.001   2.511 (1.884--3.349)    \<0.001
  Tumor size (\>3 *vs* ≤3), cm                      1.985 (1.439--2.739)       \<0.001                    1.856 (1.425--2.418)   \<0.001   1.983 (1.486--2.645)    \<0.001
  PSM (yes *vs* no)                                 2.319 (1.546--3.480)       \<0.001                    1.865 (1.290--2.694)   0.001     2.118 (1.453--3.087)    \<0.001
  Tumor architecture (Sessile *vs* Papillary)       3.675 (2.480--5.447)       \<0.001                    2.500 (1.874--3.335)   \<0.001   2.928 (2.114--4.055)    \<0.001
  CVH (yes *vs* no)                                 2.435 (1.825--3.248)       \<0.001                    2.045 (1.595--2.622)   \<0.001   2.237 (1.722--2.906)    \<0.001
  Adjuvant chemotherapy (yes *vs* no)               0.963 (0.731--1.268)       0.787                      1.128 (0.896--1.420)   0.304     0.889 (0.693--1.139)    0.351
  WBC (≥8.3 *vs* \<8.3, ×10^9^ l^−1^)               1.772 (1.305--2.407)       \<0.001                    1.455 (1.111--1.904)   0.006     1.577 (1.189--2.092)    0.002
  Platelet Count (≥230 *vs* \<230, ×10^9^9 l^−1^)   2.111 (1.592--2.799)       \<0.001                    1.634 (1.276--2.091)   \<0.001   1.711 (1.317--2.222)    \<0.001
  ALP (≥90 *vs* \<90, U l^−1^)                      1.782 (1.338--2.372)       \<0.001                    1.396 (1.092--1.785)   0.008     1.497 (1.153--1.945)    0.002
  LDH (\> 220 *vs* ≤220, U l^−1^)                   1.613 (1.145--2.272)       0.006                      1.485 (1.109--1.989)   0.008     1.553 (1.141--2.113)    0.005
  NLR (≥2.5 *vs* \<2.5)                             2.362 (1.749--3.190)       \<0.001                    1.854 (1.458--2.358)   \<0.001   2.104 (1.617--2.737)    \<0.001
  AGR (\<1.45 *vs* ≥1.45)                           2.381 (1.781--3.183)       \<0.001                    1.818 (1.438--2.298)   \<0.001   2.141 (1.656--2.767)    \<0.001
  Fibrinogen (≥4.025 *vs* \<4.025, g l^−1^)         3.965 (2.998--5.243)       \<0.001                    2.855 (2.265--3.598)   \<0.001   3.281 (2.559--4.206)    \<0.001

LVI: lymphovascular invasion; pT: pathological tumor; CVH: concomitant variant histology; PSM: positive surgical margins; WBC: white blood cell; ALP: alkaline phosphatase; LDH: lactate Dehydrogenase; NLR: neutrophil-to-lymphocyte ratio; AGR: albumin-to-globulin ratio; HR: hazard ratio; BMI: body mass index; OS: overall survival

### Clinical utility of the prediction models {#sec3-8}

We calculated the c-index to determine the predictive accuracy of the multivariate models for survival outcomes (**[Table 4](#T5){ref-type="table"}**). The base model was built based on tumor grade, stage, lymph node invasion, tumor size, and CVH; the predictive accuracies for CSS, RFS, and OS were 76.2%, 72.4%, and 75.0%, respectively (derived from the multivariate analyses). The predictive accuracy improved upon adding each laboratory biomarker, including ALP, NLR, and fibrinogen (these were significant in the multivariate models), into the base model. The largest improvement was observed when fibrinogen was added to the base model (c-index improvements for CSS, RFS, and OS were 0.032, 0.020, and 0.028, respectively).

###### 

Improvement in discrimination when adding preoperative laboratory factors to the base model

  Model            C-index for CSS   Improvement   C-index for RFS   Improvement   C-index for OS   Improvement
  ---------------- ----------------- ------------- ----------------- ------------- ---------------- -------------
  Base models^a^   0.762                           0.724                           0.750            
  \+ ALP           0.774             0.012         0.732             0.008         0.761            0.011
  \+ NLR           0.778             0.016         0.737             0.013         0.765            0.015
  \+ Fibrinogen    0.794             0.032         0.744             0.020         0.778            0.028

^a^The base models included tumor grade, stage, lymph node invasion, tumor size, and concomitant variant histology. ALP: alkaline phosphatase; NLR: neutrophil-to-lymphocyte ratio; CSS: cancer-specific survival; RFS: disease recurrence-free survival; OS: overall survival

Finally, decision curve analyses were performed to assess the clinical utility of the above findings (**[Figure 2a](#F2){ref-type="fig"}**). Because these models assist in identifying patients who require more aggressive pre- and postoperative treatments (such as adjuvant therapy, although it remains controversial in the treatment of patients with UTUC), we assumed that a patient would exhibit a relatively high rate of disease recurrence or death before receiving treatment intervention. Therefore, the threshold probability for the decision curve was up to 50%. Our results showed a significant net benefit for CSS gained by adding fibrinogen to the base model when the threshold ability was 0.3--0.5; in contrast, the net benefit gained by adding ALP or NLR to the base model was not obvious (**[Figure 2](#F2){ref-type="fig"}**).

![Decision curve analyses comparing the added benefit of ALP, NLR, or fibrinogen in addition to standard pathologic characteristics for the outcomes of (**a**) CSS, (**b**) RFS, and (**c**) OS. ALP: alkaline phosphatase; NLR: neutrophil-to-lymphocyte ratio; CSS: cancer-specific survival; RFS: disease recurrence-free survival; OS: overall survival.](AJA-22-177-g002){#F2}

DISCUSSION {#sec1-4}
==========

Our results suggest that elevated fibrinogen is an independent predictor for adverse pathological outcomes and worse survival outcomes in patients with UTUC. In addition, we demonstrate that the addition of fibrinogen may improve the predictive accuracy of the prediction models; most importantly, we reveal an added benefit for CSS prediction when fibrinogen was added to the base model. To the best of our knowledge, this is the largest single-center retrospective study to investigate the prognostic role of fibrinogen among Chinese patients who had received RNU to treat UTUC.

Using blood-based markers (including NLR,[@ref20] fibrinogen,[@ref13] C-reactive protein \[CRP\],[@ref21] and albumin-to-globulin ratio[@ref22]) from laboratory examination to predict oncologic outcomes in UTUC is not a novel concept. According to the most recent EAU guidelines, only NLR has been recommended as a preoperative risk factor in UTUC. Therefore, we sought to explore the predictive value of fibrinogen based on several published reports, which showed that an elevated fibrinogen level was an independent risk factor for poor survival in UTUC. Of note, our study showed that both NLR and fibrinogen were independent prognostic factors for UTUC, but that fibrinogen might perform better than NLR. In the multivariate Cox regression model, the HRs of fibrinogen versus NLR were 2.33 versus 1.83 for CSS, 2.09 versus 1.56 for RFS, and 2.09 versus 1.67 for OS. More importantly, the addition of fibrinogen, but not NLR, to the base model achieved a net benefit in the decision curve analysis. Thus, fibrinogen might be a better prognostic predictor than NLR for UTUC.

Plasma fibrinogen, an important factor reflecting an individual\'s coagulation function, is routinely measured before surgery. Tanaka *et al*.[@ref13] first described the prognostic role of pretreatment fibrinogen level in patients with localized UTUC in a Japanese population. The study enrolled 218 patients, and the results showed that fibrinogen \>450 mg dl^−1^ independently predicted worse pathological features and survival outcomes (CSS and RFS). Subsequently, data from Europe[@ref14] and China (East[@ref15] and North[@ref23]) also supported the independent predictive value of fibrinogen in UTUC. Nevertheless, most of these studies incorporated relatively small numbers of cases with short follow-up durations, which made their results relatively inconclusive. In addition, different cutoff values of fibrinogen were reported in these studies, limiting its use for clinical reference. Our study showed that fibrinogen could not only independently predict outcomes in UTUC, but that it increased the discriminative accuracy of predicting survival outcomes in UTUC and achieved an added net benefit for CSS in the decision curve analysis, based on providing additional information for risk stratification in UTUC.

According to our ROC analysis, the optimal cutoff value was determined to be 4.025 g l^−1^. The area under the curve (AUC) was 0.689, and the Youden index was 0.316, with a sensitivity of 57.8% and a specificity of 74.7%. In the study conducted by Wang *et al*.[@ref8] in prostate cancer, their cutoff value of fibrinogen was 3.225 g l^−1^, and the AUC was 0.692, with a sensitivity of 68.3% and a specificity of 65.7%. Both studies had comparable AUC values (0.689 *vs* 0.692), and sensitivity and specificity all exceeded 50%. It should be noted that using fibrinogen alone to predict survival outcomes might be inappropriate in current clinical practice (57.8% sensitivity); we, thus, incorporate this parameter in our multivariate models; and the predictive accuracy could reach approximately 80% when fibrinogen was added.

To date, progress has been made with regard to determining the potential mechanism by which high fibrinogen level contributes to worse oncologic outcomes among cancer patients. Tumor cells and tumor-associated macrophages might induce elevated fibrinogen levels, and fibrinogen is a determinant of metastatic potential.[@ref24] *In vitro* assays have demonstrated that fibrinogen can promote tumor cell proliferation[@ref7] and migration[@ref25][@ref26] through various signal pathways. An *in vivo* study conducted by Steinbrecher *et al*.[@ref27] further demonstrated that fibrinogen contributed to tumor progression through interaction with alpha(M)beta(2). Taken together, these data indicate that the elevated fibrinogen level caused by tumor cells promotes tumor cell invasion and metastasis, which might explain its predictive significance in UTUC.

In addition to fibrinogen, our study revealed that postoperative factors such as tumor stage and grade, CVH, and lymph node involvement independently predicted CSS, RFS, and OS; these findings were consistent with published literature.[@ref2] Compared with these pathological predictors, fibrinogen is advantageous in that it provides easy preoperative accessibility and a cost-effective approach for determining the necessity of early intervention before surgery (*e.g*., neoadjuvant therapy), as well as for assisting in identifying the best candidates for such interventions. Nonetheless, we did not find an independent prognostic value for LVI and PSM in this cohort, although previous studies revealed that these parameters were useful in this regard.[@ref28][@ref29] Research on UTUC remains limited because of its low morbidity. Our study had the largest sample size for exploration of the prognostic significance of fibrinogen in UTUC and provided useful information regarding UTUC in the West Chinese population.

As with all retrospective studies, this study was limited by its study design, which might lead to selection bias. Although we strictly limited our study population, we were unable to completely exclude those whose condition might affect the plasma fibrinogen level. In addition, we were unable to assess the potential influence of some factors, such as CRP (reportedly valuable in the prognosis of UTUC[@ref30]) because they were not routinely assessed preoperatively in our center. Moreover, data on postoperative chemotherapeutic regimens were incomplete, hindering analyzing the effects of the types, dosages, and duration of these drugs on prognosis. Furthermore, the potential role of neoadjuvant therapy remains unclear because our study cohort did not receive this treatment. Further prospective multicenter studies are warranted to support our findings.

CONCLUSIONS {#sec1-5}
===========

Preoperative fibrinogen is a strong independent factor associated with both adverse pathological features and survival outcomes in UTUC. It might be a better indicator than NLR in predicting oncologic outcomes in UTUC. Adding it into the prediction models might be valuable which might aid in clinical decision-making.
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###### 

The optimal fibrinogen cutoff level (4.025 g l^−1^) was determined from ROC analysis. The AUC was 0.689, and the Youden index was 0.316, with a sensitivity of 57.8% and a specificity of 74.7%. ROC: receiver-operating characteristic; AUC: area under the curve; CI: confidence interval.
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